Apyx Medical appoints Chairman Stavros Vizirgianakis as Executive Chairman; grants 450,000 RSUs

Apyx Medical Corp

Stavros Vizirgianakis appointed Executive Chairman effective June 11, 2026; will lead strategic initiatives and investor engagement.
Receives 450,000 RSUs: 150,000 vest immediately, 150,000 over 12 months starting year 1, 150,000 over 12 months starting year 2.
No cash compensation for the role; only expense reimbursement.
Unvested RSUs fully accelerate upon a Change of Control.
Vizirgianakis will not be an officer or employee, nor designated as an executive officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.